Navigation Links
The Samuel Waxman Cancer Research Foundation awards more than $3.1 million in grants
Date:6/30/2011

NEW YORK This year, the Samuel Waxman Cancer Research Foundation awarded individual grants to six new researchers in addition to funding 18 collaborative grants and three ongoing individual grants. The Foundation expanded its scientific grants program to a total of more than $3.1 million.

"Scientists are moving new discoveries on how to reprogram the abnormal function of enzymes and genes into therapies to eradicate cancer stem cells," said Samuel Waxman, M.D., the Founder and Scientific Director of the SWCRF. "We hope you will be as excited as the members of Scientific Advisory Board who recommended these projects because they represent the best in cancer research."

The 2011-2012 collaborative research grant recipients are:

  • Julio A. Aguirre-Ghiso, Ph.D., Eduardo F. Farias, Ph.D., Mount Sinai School of Medicine: Regulation of Disseminated Tumor Cell Fate by RARb and NR2F1 Signaling

  • Robert Casero, Ph.D., Stephen Baylin, M.D., Cynthia Zahnow, Ph.D., Johns Hopkins University: DNA Hypermethylation Module for Stemness in Cancer

  • Anthony Capobianco, Ph.D., Alexander MacKerell, Ph.D., University of Miami; University of Maryland: Exploitation of the Notch Pathway to Develop Novel Anti-Cancer Therapeutic

  • Ronald M. Evans, Ph.D., Reuben Shaw, Ph.D., Salk Institute for Biomedical Studies: Molecular Mechanisms and the Role of Inflammation in Diet-Induced Intestinal Cancer

  • Paul Fisher, M.Ph., Ph.D., Devanand Sarkar, MBBS, Ph.D., Virginia Commonwealth University: LSF as Oncogene and Target for Therapies in Hepatocellular Carcinoma

  • Doris Germain, Ph.D., Samuel Waxman, M.D., Mount Sinai School of Medicine: Proving the Activation of the Cyclin D1-STAT3 Network as a Biomarker of Response to Endocrine Therapy of Breast Cancer

  • Alan Friedman, M.D., Albert Baldwin, Jr., Ph.D., Johns Hopkins University, University of North Carolina, Chapel Hill: Inducing Apoptosis in Cancer by Targeting NF-kB and C/EBP

  • Shai Izraeli, M.D., John Crispino, Ph.D., Sheba Medical Center, Tel Aviv University, Northwestern University: CRLF2, JAK2 and Trisomy 21 in Acute Lymphoblastic Leukemia

  • Yongkui Jing, Ph.D., Ruibao Ren, M.D., Ph.D., Mount Sinai School of Medicine, Brandeis University: Development of Novel a, b-unsaturated Carbonyl Compounds as Therapeutic Agents in Myeloid Leukemia

  • Jonathan D. Licht, M.D., Wilson Miller, M.D., Ph.D., Northwestern University; Jewish General Hospital: Oncoproteins and the Response to Anti-Tumor Agents in Hematological Malignancy

  • Josep M. Llovet, M.D., Mount Sinai School of Medicine: Liver Cancer

  • Ari Melnick, M.D., Alexander MacKerell, Ph.D., and Gilbert Priv, Ph.D., Weill Cornell Medical College, University of Maryland, University of Toronto: Therapeutic Targeting of Oncogenic Transcriptional Repressor Proteins

  • Benjamin G. Neel, M.D., Ph.D., Garry P. Nolan, Ph.D., Ontario Cancer Institute, Stanford University School of Medicine: Characterization of Ovarian Tumor Initiating Cells by Mass Cytometry

  • Frank J. Rauscher III, Ph.D., Arthur Zelent, Ph.D., Wistar Institute; Institute of Cancer Research, London: Targeting the Snail Machinery that Controls EMT Differentiation Program During Metastasis

  • Yolanda Sanchez, Ph.D., Ethan Dmitrovsky, M.D., Duane Compton, Ph.D., Dartmouth School of Medicine: Overcoming Oncogene Addiction by Targeting Genomic Stability

  • Yang Shen, Ph.D., Sai-Juan Chen, Ph.D., Zhu Chen, M.D., Ph.D., Ethan Dmitrovsky, M.D., Jiang Zhu, Ph.D., Samuel Waxman, M.D., Arthur Zelent, Ph.D., Shanghai Institute of Hematology, Dartmouth School of Medicine, Mount Sinai School of Medicine, Institute of Cancer Research, London: Collaborative Grant between SIH and SWCRF

  • William Weiss, M.D., Ph.D., Kevan M. Shokat, Ph.D., Mark Lemmon, Ph.D., Albert Baldwin Jr., Ph.D., University of California, San Francisco, University of Pennsylvania, University of North Carolina, Chapel Hill: HER Family Kinases and Oncogene Addiction

  • Arthur Zelent, Ph.D, Ming-Ming Zhou, Ph.D., Institute of Cancer Research, London; Mount Sinai School of Medicine: Modulating Transcription Repressor Sin3 for Targeted Epigenetic Cancer Therapy

The 2011-2012 individual research grant recipients are:

  • Nabeel Bardeesy, Ph.D., Massachusetts General Hospital: Elucidation and Targeting of Epigenetic Reprogramming Pathways in Pancreatic Cancer

  • Ravi Bhatia, M.D., City of Hope: Targeting the Leukemia Stem Cell in CML

  • Christopher A. French, M.D., Jay Bradner, M.D., Brigham and Women's Hospital, Dana-Farber Cancer Institute: Targeting the Tumor Epigenome in NUT Midline Carcinoma

  • Margaret Goodell, Ph.D., Baylor College of Medicine: Investigating the Role of DNMT3A in Development of Myeloid Malignancies

  • Scott Hiebert, Ph.D., Vanderbilt University: HDAC3 as a Therapeutic Target in BCL6-dependent Lymphoma

  • Warren Pear, M.D., Ph.D., University of Pennsylvania: Targeting Tribbles in Cancer

  • Erwin G. Van Meir, Ph.D., Emory University School of Medicine: Reprogramming Ewing Sarcoma with a New Small Molecule Targeting the EWS-FLI1 Oncoprotein

  • Robert A. Weinberg, Ph.D., Whitehead Institute for Biomedical Research: Formation and Maintenance of Breast Cancer Stem Cells by Paracrine and Autocrine Signaling

  • Xiong Yue, Ph.D., University of North Carolina, Chapel Hill: Mechanisms of Oncometabolytes in Epigenetics and Cancer


'/>"/>

Contact: Jenny Song
jsong@waxmancancer.org
212-867-4502
Samuel Waxman Cancer Research Foundation
Source:Eurekalert

Related medicine news :

1. Enhancing arrest of cell growth to treat cancer in mice
2. Paxil Blocks Tamoxifen, Lowers Survival Odds Against Breast Cancer
3. The National Coalition for Cancer Survivorship Joins the Commission on Cancer
4. Low forms of cyclin E reduce breast cancer drugs effectiveness
5. Racial disparities persist in the diagnosis of advanced breast cancer and colon cancer in the U.S.
6. Soft drinks may increase risk of pancreatic cancer
7. UH Case Medical Center researchers publish promising findings for advanced cervical cancer
8. Genes Play Role in Prognosis With Non-Small Cell Lung Cancers
9. Single gene mutation induces endometrial cancer
10. Certain genetic profiles associated with recurrence-free survival for non-small cell lung cancer
11. Molecular pathways linked to sex, age affect outcomes in lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2017)... ... ... Doorknobs are for convenience, deadbolts are for security. , There are many ... an alarm system installed. But unless there is a working deadbolt lock that is ... Premier Locksmith in Killeen, TX says: “In the majority of home burglaries, intruders use ...
(Date:6/23/2017)... MA (PRWEB) , ... June 23, 2017 , ... ... Care Reconciliation Act (BCRA), their proposed healthcare bill to repeal and replace the ... May, the Senate bill would make significant cuts to Medicaid, a public health ...
(Date:6/23/2017)... Valley, CA (PRWEB) , ... June 23, 2017 , ... ... Blue Belle, were recently denied entry to the JFK Virgin Atlantic lounge. , ... her into a wheelchair six years ago, Bensko dedicated her life to supporting our ...
(Date:6/23/2017)... ... June 23, 2017 , ... Ensuring meat products have reached ... the importance of correctly using a meat thermometer. The videos feature University of ... on consumer food safety habits. Dr. Bruhn explains the variety of meat thermometers ...
(Date:6/23/2017)... ... 23, 2017 , ... PureLife Dental is pleased to announce that California Dental ... As part of the amalgam separator endorsement, all CDA members may purchase an ECO ... the retail value. This partnership between PureLife and CDA is especially timely as it ...
Breaking Medicine News(10 mins):
(Date:6/8/2017)... 2017  Less than a month ago, amateur hackers ... companies, including hospital networks, in over 150 countries. ... the largest online extortion attempts ever recorded. With the ... is imperative that providers understand where the risks lie, ... — and many other very real cyber threats.  ...
(Date:6/7/2017)... 7, 2017  Novavax, Inc., (Nasdaq: NVAX ) ... 2 trials of its RSV F protein recombinant nanoparticle vaccine ... have been published in the journal Vaccine ... in prior scientific conferences). The Company previously announced top ... is developing the RSV F Vaccine with the goal of ...
(Date:6/3/2017)... INDIANAPOLIS , June 3, 2017  Eli ... today announced that results from the Phase 3 ... kinase (CDK)4 & 6 inhibitor, in combination with ... treatment with fulvestrant alone in women with hormone-receptor-positive ... advanced breast cancer who have relapsed or progressed ...
Breaking Medicine Technology: